Compounds > bismuth
Page last updated: 2024-08-26

bismuth and Peritoneal Neoplasms

bismuth has been researched along with Peritoneal Neoplasms in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (33.33)18.2507
2000's2 (33.33)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alke, A; Blechert, B; Bruchertseifer, F; Drecoll, E; Essler, M; Gaertner, FC; Miederer, M; Morgenstern, A; Müller, JM; Seidl, C; Senekowitsch-Schmidtke, R; Vallon, M1
Beck, R; Bruchertseifer, F; Quintanilla-Martinez, L; Seidl, C; Senekowitsch-Schmidtke, R; Zöckler, C1
Blechert, B; Bruchertseifer, F; Essler, M; Gärtner, FC; Morgenstern, A; Neff, F; Seidl, C; Senekowitsch-Schmidtke, R1
Apostolidis, C; Beck, R; Buchhorn, HM; Morgenstern, A; Saur, D; Schwaiger, M; Seidl, C; Senekowitsch-Schmidtke, R1
Atcher, RW; Culbertson, S; Rotmensch, J; Schwartz, JL; Whitlock, JL1
Alvarez, VL; Hauler, JA; Simonson, RB; Ultee, ME1

Other Studies

6 other study(ies) available for bismuth and Peritoneal Neoplasms

ArticleYear
Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells.
    PloS one, 2009, May-27, Volume: 4, Issue:5

    Topics: Animals; Antineoplastic Agents; Bismuth; Cell Line, Tumor; Cell Nucleus; Drug Delivery Systems; Endocytosis; Humans; Isotope Labeling; Mice; Pentetic Acid; Peptides; Peritoneal Neoplasms; Radioisotopes; Tissue Distribution; Xenograft Model Antitumor Assays

2009
177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi.
    European journal of nuclear medicine and molecular imaging, 2011, Volume: 38, Issue:2

    Topics: Animals; Antibodies, Monoclonal; Bismuth; Blood Cell Count; Cell Line, Tumor; Disease Models, Animal; Drug Stability; Female; Humans; Immunoconjugates; Lutetium; Mice; Peritoneal Neoplasms; Radioimmunotherapy; Radioisotopes; Radiotherapy Dosage; Stomach Neoplasms; Time Factors

2011
Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis.
    European journal of nuclear medicine and molecular imaging, 2012, Volume: 39, Issue:4

    Topics: Actinium; Animals; Bismuth; Cell Line, Tumor; Disease Models, Animal; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Kidney; Mice; Organometallic Compounds; Pentetic Acid; Peptides; Peritoneal Neoplasms; Radioisotopes; Treatment Outcome; Xenograft Model Antitumor Assays

2012
Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imaging.
    European journal of nuclear medicine and molecular imaging, 2007, Volume: 34, Issue:6

    Topics: Animals; Bismuth; Cell Line, Tumor; Diagnostic Imaging; Luciferases; Luminescence; Mice; Mice, Nude; Neoplasm Transplantation; Peritoneal Neoplasms; Radioimmunotherapy; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Stomach Neoplasms; Transfection

2007
Comparison of sensitivities of cells to X-ray therapy, chemotherapy, and isotope therapy using a tumor spheroid model.
    Gynecologic oncology, 1994, Volume: 55, Issue:2

    Topics: Animals; Bismuth; Cisplatin; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Peritoneal Neoplasms; Radioisotopes; Radiotherapy; Tumor Cells, Cultured

1994
Radioimmunotherapy of peritoneal human colon cancer xenografts with site-specifically modified 212Bi-labeled antibody.
    Cancer research, 1990, Feb-01, Volume: 50, Issue:3 Suppl

    Topics: Animals; Antibodies, Monoclonal; Bismuth; Colonic Neoplasms; Humans; Mice; Neoplasm Transplantation; Peritoneal Neoplasms; Radioisotopes; Survival Rate; Transplantation, Heterologous

1990